GlassScriptPhysician profile
Katherine Michelle St Clair
NPI 1831412758
$5,355.70
in general payments reported to CMS, 2019-2025
23 companies · $807 in 2025
The $807 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,135 · 2022: $1,318 · 2023: $1,042 · 2024: $1,055 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.82 |
| Education | $178.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,315.45 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $732.82 | 2021-2025 | Cabtreo, Arazlo, Jublia |
| Abbvie INC. | $545.22 | 2021-2025 | |
| Genzyme Corporation | $526.01 | 2021-2025 | |
| Janssen Biotech, INC. | $350.90 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $294.46 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $219.28 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $218.84 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $164.99 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $156.66 | 2021-2022 | |
| Amgen INC. | $151.35 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $144.60 | 2021-2023 | |
| Leo Pharma INC. | $141.06 | 2021-2024 | Adbry |
| Almirall LLC | $67.56 | 2023-2024 | Seysara |
| Galderma Laboratories, L.P. | $53.04 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $52.37 | 2021-2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $51.37 | 2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $44.60 | 2021-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $38.45 | 2023-2024 | Sotyktu |
| Incyte Corporation | $28.82 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.82 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $15.91 | 2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $15.12 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine St Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.